Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astex Therapeutics presents new cancer data at AACR

Astex Therapeutics presents new cancer data at AACR

8th April 2013

Astex Therapeutics is attending the American Association for Cancer Research annual meeting in Washington DC this week in order to present new findings on a number of its cancer agents.

The company has had 13 abstracts covering internal and partner-funded pipeline product data accepted for presentation at the event, which commenced on April 6th and runs until April 10th.

During the conference, Astex will discuss data showcasing the performance of its novel hypomethylating agent SGI-110 in the treatment of ovarian and lung cancer, as well as information on its prostate cancer therapy AT13387.

Meanwhile, two of the four collaboratively-funded programmes in our portfolio – the PKB/Akt inhibitor AZD5363 and the CDK4/6 inhibitor LEE011 – will have their ongoing clinical development supported by promising new findings.

Dr James Manuso, chairman and chief executive officer at Astex, said: "AACR will be a foundational meeting for presenting significant data supporting our clinical programmes. Additional data presentations are anticipated for future meetings."

Astex enjoyed strong growth during the 2012 business year thanks to the European commercial launch of Dacogen, its new therapy for acute myeloid leukaemia.ADNFCR-8000103-ID-801568211-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.